TENX

The latest analyst update on Tenax Therapeutics trims the fair value estimate from US$12.56 to US$9.63, a reduction of about 23% in the modeled price target.

Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population.

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc.

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)

Despite the miss, a subgroup of patients with more severe disease showed more meaningful benefit - data Tenax plans to submit to the FDA and EMA.

The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom endpoint, although prespecified subgroup and biomarker findings are prompting Tenax to pursue a revised registrational strategy with the FDA.

The biotech firm’s experimental drug TNX-103 failed to meet the main goal of a late-stage study in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc.

The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock.